

## **Influenza hospitalization burden by subtype, age, comorbidity and vaccination status: 2012/13 to 2018/19 seasons, Quebec, Canada**

Sara Carazo\*, MD PhD<sup>1,2</sup> – Charles-Antoine Guay\*, MD MSc<sup>1,2,3,4</sup> (co-first authors) – Danuta M Skowronski, MD FRCPC<sup>5</sup> – Rachid Amini, MD MSc<sup>1</sup> – Hugues Charest, PhD<sup>6,7</sup> – Gaston De Serres, MD PhD<sup>1,2,8</sup> – Rodica Gilca, MD PhD<sup>1,2,8</sup>

<sup>1</sup>Biological risks unit. Institut national de santé publique du Québec, Quebec City, Quebec, Canada

<sup>2</sup>Faculty of medicine, Laval University, Quebec City, Quebec, Canada

<sup>3</sup>Pulmonary Hypertension Research Group, Centre de Recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, Canada.

<sup>4</sup>Département des sciences de la santé communautaire, Faculté de médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Canada.

<sup>5</sup>Communicable Diseases and Immunization Services, British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada

<sup>6</sup>Laboratoire de Santé Publique du Québec, Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Quebec, Canada

<sup>7</sup>Faculty of medicine, Université de Montréal, Montreal, Quebec, Canada

<sup>8</sup>Centre Hospitalier Universitaire (CHU) de Québec–Université Laval Research Center, Quebec City, Quebec, Canada

\*SC and CAG contributed equally to this manuscript

### **Corresponding author:**

Charles-Antoine Guay

Centre de Recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec

2725, chemin Sainte-Foy, Quebec City, Quebec, Canada, G1V 4G5

e-mail: [charles-antoine.guay.1@ulaval.ca](mailto:charles-antoine.guay.1@ulaval.ca)

**40-word summary:** This hospital-based study involving systematic PCR testing over seven seasons revealed important differences in influenza hospitalization risk by subtype, age, comorbidity, and vaccination status. The findings highlight the need for data-driven decision-making to optimize vaccination strategies and minimize healthcare burden.

Abstract word count: 250

Main text word count: 2987



## ABSTRACT

**Background.** The primary objective of influenza immunization programs is to reduce the risk and burden of severe outcomes. To inform optimal program strategies, we monitored influenza hospitalizations over several seasons of varying subtype predominance, stratified by age, comorbidity and vaccination status.

**Methods.** We assembled data from an active hospital-based surveillance network involving systematic swabbing and PCR-confirmation of influenza virus infection by type/subtype during peak-weeks of seven influenza seasons (2012/13 to 2018/19) in Quebec, Canada. We estimated seasonal, population-based incidence of influenza-associated hospitalizations (interpreted as risk) by subtype, age, comorbidity and vaccine status, and derived the number-needed-to-vaccinate to prevent one hospitalization per stratum.

**Results.** The average seasonal incidence of influenza-associated hospitalization was 89/100,000 (95%CI: 86, 93), lower during A(H1N1) (49-82/100,000) than A(H3N2) seasons (73-143/100,000). Overall risk followed a J-shaped age pattern, highest among infants 0-5 months and adults  $\geq 75$  years. Hospitalization risks were highest for children  $< 5$  years during A(H1N1) but for adults  $\geq 75$  years during A(H3N2) subtype-predominant seasons. Age-adjusted hospitalization risks were 7-fold higher among individuals with versus without comorbidities (214 versus 30/100,000). The number-needed-to-vaccinate to prevent hospitalization was 82-fold lower for  $\geq 75$ -years-olds with comorbidity ( $n=1,995$ ), who comprised 39% of all hospitalizations, than for healthy 18-64-year-olds ( $n=163,488$ ), who comprised just 6% of all hospitalizations.

**Conclusions.** In the context of broad-based influenza immunization programs (targeted or universal), severe outcome risks should be simultaneously examined by subtype, age, comorbidity, and vaccine status. Policymakers require such detail to prioritize further promotional efforts and expenditures toward the greatest and most efficient program impact.

## INTRODUCTION

Seasonal influenza remains one of the leading causes of morbidity and mortality globally, despite broad-based vaccination efforts. In the United States (US) alone, seasonal influenza accounts for >\$3 billion in direct annual health care costs, most of which is attributable to the nearly 400,000 hospitalizations that accrue on average annually(1). The primary goal of most influenza vaccination programs is to reduce the risk and burden due to severe outcomes (hospitalizations and deaths). Even in the context of high vaccine coverage among target groups and universal influenza immunization programs throughout much of North America (including the US and most provinces of Canada), estimates of the residual hospitalization burden due to influenza are seldom examined by vaccination status(2–4).

Like most countries of Europe, the influenza immunization program in the province of Quebec, Canada, is targeted toward those at highest risk of severe outcome, notably elderly adults and those  $\geq 6$  months of age with underlying comorbidity(5,6). All jurisdictions, however, struggle to understand which strategies may have the greatest and most efficient impact in further reducing the residual hospitalization burden (e.g. existing targeted with enhanced promotion, expanded targeted and/or universal). To explore this question, we assembled data from an active hospital-based respiratory virus surveillance network and examined influenza-associated hospitalisation risks stratified simultaneously by age, comorbidity, and vaccination status during seven influenza seasons (2012-13 to 2018-19) of varying type/subtype predominance.

## METHODS

### 1. *Hospital-based surveillance.*

The hospital-based surveillance network in the province of Quebec included two community and two academic/tertiary acute-care regional hospitals, serving nearly 10% of the overall Quebec population (8,3M in 2018)(7). Patients were recruited during influenza epidemic peak-weeks. The latter were defined by percent positivity reported by a sentinel laboratory surveillance network in Quebec comprised of >40 hospital laboratories that test >100,000 respiratory specimens for influenza virus, on average per year. The peak-week period began when influenza positivity was  $\geq 15\%$  for two consecutive weeks and ended when positivity first fell  $< 15\%$  or when the budgeted sample size was exhausted (~800-1000 specimens per season) (**Supplementary Figure 1**).

During these seasonal peak-week periods, all patients presenting to participating hospital emergency departments with an acute respiratory infection (ARI: fever/feverishness in absence of an identifiable non-respiratory cause, or cough, or sore throat) were systematically swabbed. Patients admitted for  $\geq 24$

hours were invited to participate in the study. Demographic and clinical details were collected on consenting patients by research nurses through patient (or legal representative) interview and chart review. Vaccination status was based on self-reported receipt of seasonal influenza vaccine at least 14 days before symptom onset. Patients missed by the nurse because of early discharge or who refused or were unable to participate still contributed to surveillance with their laboratory results aggregated by age category.

Nasal specimens collected on flocked swabs were tested by the multiplex Luminex® RVP FAST version 1 or the NxTAG RPP assays which detects influenza A (seasonal H3N2 and H1N1 subtypes), influenza B, and 15 other respiratory viruses(8). The two assays are approved for diagnosis by Health Canada authorities.

## 2. Estimated hospitalizations

Influenza-associated hospitalizations were estimated (stratified by age group, comorbidity and/or season) with adjustment for varying peak-week contribution per season, test sensitivity and percentage participation (**Supplementary Figure 1, Supplementary Table 1**). To account for varying peak-week contribution to the overall seasonal span, we derived the peak-week influenza detections as a percentage of all influenza detections across the season by the sentinel laboratory surveillance network (53% to 73%). We multiplied the inverse of that seasonal peak-week percent contribution by the peak-week tally of hospitalizations in order to estimate the number of hospitalizations for each full season. Hospitalization may be delayed in relation to symptom onset and test sensitivity is reduced among patients consulting >8 days post onset(9). We therefore applied the influenza positivity of patients consulting ≤8 days post-onset to the tally of patients consulting >8 days post-onset (or with unknown onset date) whose multiplex results for respiratory viruses were otherwise fully negative. Finally, percentage participation (i.e. included divided by eligible individuals) ranged 59-87% by both age group and season and estimated hospitalization incidences were also adjusted for that variation.

## 3. Population denominators

Age-specific denominators for the underlying catchment area of participating hospitals were obtained from the *Institut de la statistique du Québec*(10). Age-specific denominators further stratified for comorbidity were estimated based upon respondents to a population-based vaccination survey conducted in Quebec in 2018, using the percentage that reported select comorbid conditions known to increase the risk of influenza complications, including 34%, 45% and 59% of adults 18-64, 65-74 and ≥75-years old, respectively(11). Since the survey data aggregated all adults ≥75 years, the proportion with comorbidity among age groups 75-84 and ≥85-year-olds was estimated by applying the coefficient of increase in the prevalence of multimorbidity by age reported in Quebec in 2016-17(12). For children, the

proportion with comorbidities was based on that reported by controls randomly sampled from the general Quebec population as part of previous case-control studies, including 3%, 7% and 6% for 6-23 month-, 2-4-year- and 5-17-year-olds, respectively(13,14). Because comorbidity estimates were not available for 0-5-month-olds, this group was not further stratified on that basis. Finally, age- (18-64, 65-74 and  $\geq 75$  years) and comorbidity-specific denominators were further stratified on vaccination status using average coverages extracted from the 2016 and 2018 influenza vaccine coverage surveys for the province of Quebec(11,15).

#### 4. *Estimated hospitalization incidence/risk and number-needed-to-vaccinate (NNV)*

Influenza hospitalization incidences (interpreted as risks) per 100,000 population were estimated as the adjusted number of hospitalizations divided by corresponding denominators. Estimates were stratified by season (2012-13 to 2018-19), age group (0-5 and 6-23 months, 2-4, 5-17, 18-64, 65-74, 75-84 and  $\geq 85$  years), comorbidity status ( $\geq 1$  or no comorbid condition) and vaccination status. Mean incidences were calculated using a 1000 bootstrap re-sampling with replacement method. The 95% confidence intervals (CI) were defined as the 2.5<sup>th</sup> and 97.5<sup>th</sup> percentiles of the bootstrap distribution.

The NNV to prevent one hospitalization was estimated as per below, for vaccine effectiveness (VE) of

$$30\%, 50\% \text{ and } 60\%: \text{NNV} = \frac{1}{\text{Incidence unvaccinated} - \text{Incidence assuming different VE}} \times 100,000$$

#### 5. *Ethics*

For the first three years, participating hospitals each obtained Institutional Review Board approval from Comité d'éthique de la recherche du Centre hospitalier de l'Université Laval, from Comité d'éthique de la recherche du Centre de santé et des services sociaux de Chicoutimi, from Comité scientifique et d'éthique de la recherche du Centre de santé et de services sociaux de Laval, from Comité central d'éthique de la recherche du ministre de la Santé et des Services sociaux du Centre de santé et de services sociaux du Haut-Richelieu et Centre de santé et de services sociaux de Rimouski-Neigette. Thereafter, activities were incorporated into routine provincial surveillance, mandated by the Ministry of Health, and a waiver was obtained from the Research Ethics Board of the Centre hospitalier universitaire de Québec-Université Laval.

## RESULTS

The seven influenza seasons of the study included four influenza A(H3N2) predominant seasons (2012-13, 2014-15, 2016-17 and 2017-18) and three A(H1N1) predominant seasons (2013-14, 2015-16 and 2018-19) (**Supplementary Figure 1**). Influenza B often circulated after seasonal peak weeks and was therefore less reliably captured by the hospital surveillance network.

### Population

Among the 6,545 eligible patients admitted with ARI, 4,821 (74%) consented to participate. The main reasons for non-inclusion were: missed by the study nurse (44%), unable to consent (32%), sampling or laboratory problem (8%) and refusal (6%) (**Supplementary Table 2**). Non-participants were older, more often infected with A(H3N2), and previously recruited in earlier seasons (not shown). Among the 1,171 and 3,650 hospitalized children and adults who agreed to participate, 272 (23%) and 1,682 (46%), respectively, tested influenza-positive with characteristics shown in **Table 1**. Age distribution varied substantially by influenza A subtype. Children and adults <60 years were more affected during A(H1N1)-predominant seasons, comprising 56% of hospitalizations compared to only 27% during A(H3N2) seasons. In contrast, adults ≥75 years old were disproportionately affected during A(H3N2)-predominant seasons, comprising 56% of hospitalizations compared to 26% during A(H1N1)-predominant seasons. Adults 65-74 years represented 17-18% of all hospitalizations regardless of subtype. Comorbidity was reported overall by 74% of hospitalized cases: 55% had at least one chronic cardiac and/or respiratory condition and 19% reported another chronic condition (**Table 1**). Overall, 12% of hospitalized children >6 months old and 47% of hospitalized adults had received influenza vaccine, higher among children and adults with (23% and 51%, respectively) than without (9% and 27%, respectively) comorbidities (**Figure 1**). The distribution of specific comorbidities by age group and the percent vaccinated by each is presented in **Supplementary Table 3**.

### Influenza-associated hospitalization incidence risk

In the source population of about 135,000 children and 560,000 adults, the average seasonal incidence of influenza-associated hospitalizations was 89/100,000 (95%CI: 86, 93), lower during A(H1N1) predominance (lowest in 2013-14, 49/100,000; 95%CI: 42, 56) and higher during A(H3N2) predominance (highest in 2014-15, 143/100,000; 95%CI: 130, 158) (**Table 2, Figure 2**). The average annual hospitalization risk overall was 7-fold higher among patients with (214/100,000; 95%CI: 204, 223) versus without comorbidities (30/100,000; 95%CI: 27, 32), with similar trend in all age groups and for both influenza A subtypes.

Influenza hospitalization risk followed a J-shaped pattern by age: 416/100,000 (95%CI: 308, 531) among 0-5-month-olds and 255/100,000 (95%CI: 204, 306) among 6-23-month-olds, lower in other pediatric age groups and increasing through adulthood, highest at 434/100,000 (95%CI: 392, 485) among 75-84-year-olds and 873/100,000 (95%CI: 751, 1019) among ≥85-year-olds. Patients 5-64 years had the lowest incidence of hospitalization (17 to 31/100,000). Compared with children 2-4 years of age, the risk of hospitalization was 5-fold higher for infants 0-5 months and 3-fold higher for children 6-23 months

(**Table 2, Figure 3**). Compared with 65-74-year-olds, the risk of hospitalization was 3-fold higher for 75-84-year-olds and 6-fold higher for  $\geq 85$ -year-olds. The risk of hospitalization was higher among 18-64-year-olds with comorbidity than among healthy older adults 65-74 years old.

During A(H3N2) seasons, patients aged  $\geq 75$  years were the most affected, followed by infants 0-5 months, while during A(H1N1) seasons children  $< 2$  years of age had the highest hospitalization risks (**Figure 2**). For all examined seasons, hospitalization incidences were higher in patients 6-23 months and 18-64 years during A(H1N1) versus A(H3N2) seasons.

Hospitalization risks were higher for unvaccinated individuals in all adult ages both in A(H1N1) and A(H3N2) seasons and regardless of comorbidity status. The only exception was among 18-64-year-olds with comorbidity, for whom hospitalization incidences were unexpectedly higher in vaccinated individuals (**Figure 4, Supplementary Table 4**). Overall, the ratio of hospitalization risk comparing unvaccinated to vaccinated adults was higher among those without comorbidities (ranging from 2.3 for 18-64-year-olds to 6.4 for  $\geq 85$ -year-olds) than among those with comorbidities (from 0.7 to 1.8 respectively) (**Supplementary Table 4**).

#### Number needed to vaccinate

The proportion of unvaccinated cases and the NNV per hospitalization prevented varied by age and comorbidity status (**Table 3**). Individuals  $\geq 75$  years with comorbidity represented 39% of all hospitalizations; 41% were unvaccinated and the NNV (assuming VE of 50%) to prevent hospitalization was 1,995. In contrast, healthy adults 18-64 years comprised 6% of hospitalizations; 88% were unvaccinated, and the NNV to prevent hospitalization was 163,488 (82 times higher). Healthy adults 65-74 years and those 18-64 years with comorbidity had similar NNV (respectively 35,418 vs 41,025) but the former comprised 2% of hospitalizations compared to 16% for the latter and with 80% vs 67% unvaccinated, respectively. Overall patterns were the same in sensitivity analysis ranging VE estimates from 30-60%.

## **DISCUSSION**

This hospital-based surveillance network involving systematic PCR testing during seasonal peak epidemic weeks showed important differences in influenza hospitalization risk by subtype, age, comorbidity and vaccination status. Consistent with their influenza vaccination prioritization, individuals with comorbidity and those at the extremes of age were disproportionately affected. Despite decades of recommendations and promotion efforts focused toward elderly patients and those with comorbidity,



however, a large percentage (nearly half) hospitalized with influenza were unvaccinated, with severe outcomes that should therefore still be considered at least partially preventable.

We estimated that people with comorbidity, both children and adults, were at about 5-10 times higher risk of influenza-associated hospitalization than otherwise healthy individuals. Greater risk among adults with comorbidity was also observed in the few studies from the US and United Kingdom similarly stratifying hospitalization by comorbidity(16–19). In children however, these studies reported comorbidity/healthy ratios of 0 to 0.6, corresponding to relatively higher hospitalization risks among healthy versus high-risk children <17 years(16–18). These studies, however, were conducted before the 2009 influenza pandemic and applied mathematical modelling to administrative datasets, with clinically-defined (vs. laboratory confirmed) influenza outcomes. Children with comorbidities may be under-detected in some studies relying only on secondary ICD-10 codes to identify comorbidities associated with a single, primarily respiratory, admission(16,17). In contrast, an Australian cohort study conducted between 2001 and 2010 similarly found 5-fold higher risk of influenza-associated hospitalization in children <10 years old with versus without pulmonary chronic diseases, ranging between 2-11-fold depending upon the underlying disease and pediatric age group(20).

Age and influenza type/subtype also seem to interact to predict influenza hospitalization burden, with higher rates among older adults during influenza A(H3N2) predominant seasons(4,16,17,21–25).

Although many influenza immunization programs have targeted adults  $\geq 65$  years, we show further age-related differences with finer examination of older adults. In fact, compared to 65-74-year-olds, hospitalization incidences were 1.4 to 3.9 times higher in 75-84-year-olds and 2.2 to 8.6 times higher in  $\geq 85$ -year-olds, more pronounced during A(H3N2) seasons. Moreover, healthy 65-74-year-old adults had lower hospitalization rates than 18-64-year-old adults with comorbidity. The US Influenza Hospitalization Surveillance Network reported similar ratios (2.2 to 6.4) when comparing the same age groups, also with greater differences during A(H3N2) seasons, but did not further stratify by presence of comorbidities(22,26). Similar to our findings, other studies displaying open-ended age categories  $\geq 75$  or  $\geq 80$  years showed 2-3-fold higher hospitalization incidences among individuals with comorbidity(16,23,27).

In our study, infants 0-5 months of age had higher hospitalization risks than children aged 6-23 months (1.6-fold) or 2-4 years (4.8-fold). These ratios are lower than reported in Finnish and US studies comparing infants 0-5 months to children 6-23 months (2-fold) or 2-4 years (ranging 8-15-fold)(28–31,23). Different from older adults, hospitalization risks in our study among children <5 years were higher in A(H1N1) predominant seasons (110 to 234/100,000) than A(H3N2) predominant seasons (85 to

166/100,000). Boddington et al also reported higher hospitalization rates (rate ratio 1.2) during A(H1N1) versus A(H3N2) predominant seasons based on two A(H1N1) predominant seasons between 2010/11 through 2014/15(4). The reason for differences in susceptibility and severe outcome risk by age and subtype is not clearly understood, but birth cohort effects determined by original childhood priming history have been postulated(32).

Of note in the above comparisons, studies published elsewhere did not account for vaccination status, with coverages that may differ by region, age group, and comorbidity status also likely contributing to observed differences in estimated hospitalization risks(33). Although our study was not designed to evaluate vaccine effectiveness against hospitalization, the lower incidence of hospitalization in vaccinated compared to unvaccinated individuals likely reflects, at least in part, the protective effects (risk reductions) associated with influenza vaccination. When stratifying for age, comorbidity and influenza type/subtype season, we observed lower hospitalization incidences among vaccinated compared to unvaccinated individuals in all strata except 18-64-year-olds with comorbidity. Not all comorbidities are expected to influence VE equally and this unexpectedly higher risk among vaccinated versus unvaccinated 18-64-year-olds with comorbidity may be partially explained by a higher percentage with immunosuppressive condition among vaccinated (29%) vs. unvaccinated (13%) adults 18-64 years [not displayed].

NNV derivation enables quantification of the impact of further immunization efforts, but requires accurate estimates of absolute hospitalization risks sufficiently granular to examine potential target group comparisons. Severe outcome rates have traditionally been estimated using ecologic designs and various statistical models applied to administrative and surveillance data(34,35). Validation studies comparing ecological model-based estimates to empirical measures incorporating laboratory-confirmed outcomes show the former to be unreliable in having both over- and under-estimated hospitalization rates(36). More recently, and similar to our own study, others have also used PCR-confirmed data from influenza hospitalization surveillance networks with adjustment for under-detection, population characteristics and/or extrapolation to the general population(21,37–40). Unlike our study, however, estimates elsewhere did not take into account vaccination status(21,37–40). Additional stratification on vaccine status supports NNV estimation and points to where improvements in vaccination coverage may have the greatest and most efficient impact on residual hospitalization burden. While actual NNV estimates will vary between jurisdictions, all jurisdictions would benefit from this more granular and goal-oriented monitoring approach. Understanding the distribution of influenza hospitalizations simultaneously by age, comorbidity and vaccination status reveals the proportion of preventable and

non-preventable hospitalizations by relevant target groups, and the immunization gaps to be addressed to further most efficiently reduce healthcare burden.

Our study has limitations. Sample size was limited to  $\leq 1000$  participants admitted annually across four hospitals and surveillance was conducted only during seasonal peak weeks. Consequently, we missed a large proportion of influenza B infections in the 2012-13, 2013-14, 2014-15, 2016-17 seasons.

Extrapolation of the age-distribution during peak weeks to the entire season may have biased age-specific estimates if the age distribution of influenza B cases or other influenza A sub-types differed outside these periods. Previous studies have shown higher hospitalization rates in children due to influenza B versus A(H3N2), suggesting we may have underestimated risk in younger age groups(4).

However, this would not affect the specific A(H1N1) and A(H3N2) risk comparisons. There are uncertainties in the underlying assumptions used in adjusting influenza-associated hospitalization tallies and population denominators for each stratum. Although this may affect the precision of estimates, the comparison between groups (for instance, with comorbidity versus healthy) would likely remain valid.

Despite these limitations, our systematic PCR testing of all patients presenting with ARI enhances current understanding of the influenza burden compared to other studies. For example, in the US Influenza Hospitalization Surveillance Network patients are tested by PCR or non-PCR tests at physician discretion requiring adjustment for the frequency of testing and diagnostic assay sensitivity and with potential bias based on physician preferences(37). Unlike previous publications based on secondary use of administrative data assembled for a different original purpose, our trained research nurses directly collected and verified information about comorbidity and vaccination status, thus minimizing misclassification bias(16–19).

In conclusion, influenza hospitalization risks vary substantially by subtype, age, comorbidity, and vaccination status. In the context of broad-based influenza immunization programs—targeted or universal—severe outcome surveillance should be stratified simultaneously by each of these factors to enable reliable and informative NNV derivation and comparison. Only then can policymakers derive a true sense of how further vaccination efforts and expenditures in their regions should be prioritized for optimal impact and efficiency.

## ACKNOWLEDGMENTS

We would like to thank Manale Ouakki (Institut national de santé publique du Québec) for her statistical support to perform the bootstrap estimations and France Bouchard (Centre de Recherche du CHU de Québec – Université Laval) for her work as coordinator of Quebec hospital–based surveillance network.

**Financial support.** This work was supported by the Ministère de la santé et des services sociaux du Québec.

**Author contributions.** All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. **Concept and design:** SC, CAG, DS, GDS, RG.

**Acquisition, analysis, or interpretation of data:** All authors. **Drafting of the manuscript:** SC, CAG, RG.

**Critical revision of the manuscript for important intellectual content:** All authors. **Statistical analysis:** SC, CAG. **Supervision:** GDS, RG

**Conflict of interest.** SC, RA and RG report funding from the Ministère de la santé et des services sociaux du Québec to conduct this work, paid to their institution. DS reports funding from Public Health Agency of Canada and British Columbia Center for Diseases Control Foundation for Public Health for influenza and COVID-19 studies but not pertaining to the current study; from Michael Smith Foundation for Health Research and from Canadian Institutes of Health Research for COVID-19 studies but not pertaining to the current study; all grants were paid to her institution. All other authors report no potential conflicts.

**Data availability.** Individual data not publicly available

## REFERENCES

1. Putri WCWS, Muscatello DJ, Stockwell MS, Newall AT. Economic burden of seasonal influenza in the United States. *Vaccine*. 2018 Jun 22;36(27):3960–6.
2. O’Halloran AC, Holstein R, Cummings C, Daily Kirley P, Alden NB, Yousey-Hindes K, et al. Rates of Influenza-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death by Race and Ethnicity in the United States From 2009 to 2019. *JAMA Netw Open*. 2021 Aug 24;4(8):e2121880.
3. Jules A, Grijalva CG, Zhu Y, Talbot HK, Williams JV, Poehling KA, et al. Influenza-related hospitalization and ED visits in children less than 5 years: 2000-2011. *Pediatrics*. 2015 Jan;135(1):e66-74.
4. Boddington NL, Verlander NQ, Pebody RG. Developing a system to estimate the severity of influenza infection in England: findings from a hospital-based surveillance system between 2010/2011 and 2014/2015. *Epidemiol Infect*. 2017;145(7):1461–70.
5. Ministère de la Santé et des Services Sociaux Québec. Vaccination. 2022. Flu vaccination program. Available from: <https://www.quebec.ca/en/health/advice-and-prevention/vaccination/flu-vaccination-program>
6. National Advisory Committee on Immunization. Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2022-2023 [Internet]. Public Health Agency of Canada; 2022 Jun [cited 2023 May 10]. Available from: <https://www.canada.ca/en/public-health/services/publications/vaccines-immunization/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2022-2023.html>
7. Gilca R, Amini R, Douville-Fradet M, Charest H, Dubuque J, Boulianne N, et al. Other Respiratory Viruses Are Important Contributors to Adult Respiratory Hospitalizations and Mortality Even During Peak Weeks of the Influenza Season. *Open Forum Infect Dis* [Internet]. 2014 Sep 22 [cited 2020 Jan 8];1(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281811/>
8. Jokela P, Piiparinen H, Mannonen L, Auvinen E, Lappalainen M. Performance of the Luminex xTAG Respiratory Viral Panel Fast in a clinical laboratory setting. *J Virol Methods*. 2012 Jun;182(1–2):82–6.
9. Jiang L, Lee VJM, Cui L, Lin R, Tan CL, Tan LWL, et al. Detection of viral respiratory pathogens in mild and severe acute respiratory infections in Singapore. *Sci Rep*. 2017 20;7:42963.
10. Institut de la statistique du Québec. Population et démographie. Population par année d’âge et par sexe, Québec. [Internet]. [cited 2019 Oct 7]. Available from: [http://www.bdso.gouv.qc.ca/pls/ken/ken213\\_afich\\_tabl.page\\_tabl?p\\_iden\\_tran=REPERDUKTZY49-120149785127`zH2&p\\_lang=2&p\\_m\\_o=ISQ&p\\_id\\_ss\\_domn=986&p\\_id\\_raprt=697](http://www.bdso.gouv.qc.ca/pls/ken/ken213_afich_tabl.page_tabl?p_iden_tran=REPERDUKTZY49-120149785127`zH2&p_lang=2&p_m_o=ISQ&p_id_ss_domn=986&p_id_raprt=697)
11. Dubé È, Kiely M, Ouakki M. INSPQ. 2018 [cited 2019 Oct 7]. Enquête québécoise sur la vaccination contre la grippe saisonnière et le pneumocoque et sur les déterminants de la vaccination : 2018. Available from: [https://www.inspq.qc.ca/sites/default/files/publications/2564\\_enquete\\_vaccination\\_grippe\\_pneumocoque\\_zona.pdf](https://www.inspq.qc.ca/sites/default/files/publications/2564_enquete_vaccination_grippe_pneumocoque_zona.pdf)

12. Simard M, Dubé M, Gaulin M, Trépanier PL. La prévalence de la multimorbidité au Québec: portrait pour l'année 2016-2017 [Internet]. Institut national de santé publique Québec; 2019 [cited 2019 Oct 10] p. 12. (Surveillance des maladies chroniques). Report No.: 29. Available from: [https://www.inspq.qc.ca/sites/default/files/publications/2577\\_prevalence\\_multimorbidite\\_quebec\\_2016\\_2017.pdf](https://www.inspq.qc.ca/sites/default/files/publications/2577_prevalence_multimorbidite_quebec_2016_2017.pdf)
13. Gilca R, Deceuninck G, De Serres G, Boulianne N, Sauvageau C, Quach C, et al. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. *Pediatrics*. 2011 Nov;128(5):e1084-1091.
14. Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. *PLoS Med*. 2010 Apr 6;7(4):e1000258.
15. Dubé È, Kiely M, Ouakki M. INSPQ. 2016 [cited 2019 Oct 7]. Enquête québécoise sur la vaccination contre la grippe saisonnière et le pneumocoque et sur les déterminants de la vaccination : 2016. Available from: [https://www.inspq.qc.ca/sites/default/files/publications/2234\\_enquete\\_vaccination\\_grippe\\_pneumocoque.pdf](https://www.inspq.qc.ca/sites/default/files/publications/2234_enquete_vaccination_grippe_pneumocoque.pdf)
16. Matias G, Taylor RJ, Haguinet F, Schuck-Paim C, Lustig RL, Fleming DM. Modelling estimates of age-specific influenza-related hospitalisation and mortality in the United Kingdom. *BMC Public Health*. 2016 08;16:481.
17. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status. *BMC Public Health*. 2017 21;17(1):271.
18. Cromer D, van Hoek AJ, Jit M, Edmunds WJ, Fleming D, Miller E. The burden of influenza in England by age and clinical risk group: a statistical analysis to inform vaccine policy. *J Infect*. 2014 Apr;68(4):363–71.
19. Mullooly JP, Bridges CB, Thompson WW, Chen J, Weintraub E, Jackson LA, et al. Influenza- and RSV-associated hospitalizations among adults. *Vaccine*. 2007 Jan 15;25(5):846–55.
20. Homaira N, Briggs N, Oei JL, Hilder L, Bajuk B, Snelling T, et al. Impact of influenza on hospitalization rates in children with a range of chronic lung diseases. *Influenza Other Respir Viruses*. 2019;13(3):233–9.
21. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2012 May;54(10):1427–36.
22. Centers for Disease Control and Prevention. Influenza Hospitalization Surveillance Network (FluSurvNET) [Internet]. 2022 [cited 2023 Apr 19]. Available from: <https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm>
23. Proff R, Gershman K, Lezotte D, Nyquist AC. Case-based surveillance of influenza hospitalizations during 2004-2008, Colorado, USA. *Emerg Infect Dis*. 2009 Jun;15(6):892–8.

24. Bernadou A, Sommen C, Pivette M, Hubert B. Estimating the burden of influenza-attributable severe acute respiratory infections on the hospital system in Metropolitan France, 2012-2018. *BMC Infect Dis.* 2023 Mar 6;23(1):128.
25. Langer J, Welch VL, Moran MM, Cane A, Lopez SMC, Srivastava A, et al. High Clinical Burden of Influenza Disease in Adults Aged  $\geq 65$  Years: Can We Do Better? A Systematic Literature Review. *Adv Ther.* 2023 Apr;40(4):1601–27.
26. Czaja CA, Miller L, Alden N, Wald HL, Cummings CN, Rolfes MA, et al. Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza-U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET). *Open Forum Infect Dis.* 2019 Jul 1;6(7).
27. Dao CN, Kamimoto L, Nowell M, Reingold A, Gershman K, Meek J, et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. *J Infect Dis.* 2010 Sep 15;202(6):881–8.
28. Silvennoinen H, Peltola V, Vainionpää R, Ruuskanen O, Heikkinen T. Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study. *Pediatr Infect Dis J.* 2011 Feb;30(2):e24-28.
29. Schrag SJ, Shay DK, Gershman K, Thomas A, Craig AS, Schaffner W, et al. Multistate surveillance for laboratory-confirmed, influenza-associated hospitalizations in children: 2003-2004. *Pediatr Infect Dis J.* 2006 May;25(5):395–400.
30. Poehling KA, Edwards KM, Weinberg GA, Szilagyi P, Staat MA, Iwane MK, et al. The underrecognized burden of influenza in young children. *N Engl J Med.* 2006 Jul 6;355(1):31–40.
31. Kamidani S, Garg S, Rolfes MA, Campbell AP, Cummings CN, Haston JC, et al. Epidemiology, Clinical Characteristics, and Outcomes of Influenza-Associated Hospitalizations in US Children Over 9 Seasons Following the 2009 H1N1 Pandemic. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2022 Nov 30;75(11):1930–9.
32. Budd AP, Beacham L, Smith CB, Garten RJ, Reed C, Kniss K, et al. Birth Cohort Effects in Influenza Surveillance Data: Evidence That First Influenza Infection Affects Later Influenza-Associated Illness. *J Infect Dis.* 2019 Jul 31;220(5):820–9.
33. Arriola C, Garg S, Anderson EJ, Ryan PA, George A, Zansky SM, et al. Influenza Vaccination Modifies Disease Severity Among Community-dwelling Adults Hospitalized With Influenza. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2017 15;65(8):1289–97.
34. Thompson WW, Moore MR, Weintraub E, Cheng PY, Jin X, Bridges CB, et al. Estimating influenza-associated deaths in the United States. *Am J Public Health.* 2009 Oct;99 Suppl 2:S225-230.
35. Schanzer DL, Saboui M, Lee L, Nwosu A, Bancej C. Burden of influenza, respiratory syncytial virus, and other respiratory viruses and the completeness of respiratory viral identification among respiratory inpatients, Canada, 2003-2014. *Influenza Other Respir Viruses.* 2018;12(1):113–21.

36. Gilca R, De Serres G, Skowronski D, Boivin G, Buckeridge DL. The need for validation of statistical methods for estimating respiratory virus-attributable hospitalization. *Am J Epidemiol*. 2009 Oct 1;170(7):925–36.
37. Reed C, Chaves SS, Daily Kirley P, Emerson R, Aragon D, Hancock EB, et al. Estimating influenza disease burden from population-based surveillance data in the United States. *PLoS One*. 2015;10(3):e0118369.
38. Bolotin S, Pebody R, White PJ, McMenamin J, Perera L, Nguyen-Van-Tam JS, et al. A New Sentinel Surveillance System for Severe Influenza in England Shows a Shift in Age Distribution of Hospitalised Cases in the Post-Pandemic Period. Cowling BJ, editor. *PLoS ONE*. 2012 Jan 23;7(1):e30279.
39. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. *J Infect Dis*. 2012 Jul 1;206(1):56–62.
40. Bennet R, Hamrin J, Wirgart BZ, Östlund MR, Örtqvist Å, Eriksson M. Influenza epidemiology among hospitalized children in Stockholm, Sweden 1998-2014. *Vaccine*. 2016 14;34(28):3298–302.



## FIGURE LEGENDS

**Figure 1.** Number of influenza hospitalizations in the Quebec hospital surveillance (2012-13 to 2018-19) by age group, comorbidity status and vaccination status and vaccination coverage among adults by age group and comorbidity status

Notes:

Numbers over the columns are percentage of vaccinated among each age and risk subgroup (also represented by the upper grey area of each column)

Vaccination coverages (VC) are the average of 2016 and 2018 Quebec's vaccination surveys. Estimations are representative for population with and without comorbidities for 3 age groups (18-64 years, 65-74 years and  $\geq 75$  years)

**Figure 2.** Estimated influenza-associated hospitalization rates (per 100,000) by age group and by influenza sub-type dominance season

**Figure 3.** Estimated influenza-associated hospitalization rates (per 100,000) and confidence intervals, by age group and comorbidity status, Quebec hospital surveillance (2012-13 to 2018-19)

**Figure 4.** Estimated influenza-associated annual hospitalization rates (per 100,000) by vaccination status among adults with or without comorbidity, Quebec, 2012-13 to 2018-19

Note: Vertical lines in the bars represent the 95% confidence intervals

## TABLES

**Table 1.** Characteristics of patients hospitalized with influenza by season of influenza A(H3N2) or A(H1N1) predominance

	A(H3N2) seasons <sup>a</sup>	A(H1N1) seasons <sup>b</sup>	Total
	N (%)	N (%)	N (%)
Total	1136	540	1954
Age			
0-5m	34 (2.7)	16 (2.3)	50 (2.6)
6-23m	37 (2.9)	60 (8.7)	97 (5.0)
2-4y	32 (2.5)	37 (5.4)	69 (3.5)
5-17y	32 (2.5)	24 (3.5)	56 (2.9)
18-64y	207 (16.4)	249 (36.1)	456 (23.3)
65-74y	218 (17.2)	124 (18.0)	342 (17.5)
75-84y	369 (29.2)	114 (16.55)	483 (24.7)
85+y	336 (26.6)	65 (9.43)	401 (20.5)
Sex			
Male	568 (44.9)	312 (45.3)	880 (45.1)
Female	697 (55.1)	377 (54.7)	1074 (55.0)
Comorbidity status			
Healthy	266 (21.0)	235 (34.1)	501 (25.6)
Cardiac comorbidity only	311 (24.6)	102 (14.8)	413 (21.1)
Respiratory comorbidity only	244 (19.3)	165 (24.0)	409 (20.9)
Cardiac and respiratory	161 (12.7)	105 (15.2)	266 (13.6)
Other comorbidities <sup>c</sup>	283 (22.4)	82 (11.9)	365 (18.7)
Vaccination status			
Yes	478 (37.8)	196 (28.5)	674 (34.5)
No	609 (48.1)	474 (68.8)	1083 (55.4)
Unknown	178 (14.1)	19 (2.8)	197 (10.1)
Origin of patients <sup>d</sup>			
Community	943 (74.6)	583 (84.7)	1526 (78.1)
Long term care facility	157 (12.4)	26 (3.8)	183 (9.4)
Other facilities / institutions <sup>e</sup>	165 (13.0)	77 (11.2)	242 (12.4)
Type of infection			
Influenza only	1099 (86.9)	601 (87.2)	1700 (87.0)
Influenza+RSV	34 (2.7)	14 (2.0)	48 (2.5)
Influenza+ORV <sup>f</sup>	132 (10.4)	74 (10.7)	206 (10.5)
Interval (in days) between symptom onset and sampling, mean ± standard deviation	4.6 ± 5.6	3.9 ± 4.6	4.3 ± 5.3

<sup>a</sup>2012/13, 2014/15, 2016/17 and 2017/18 seasons

<sup>b</sup>2013/14, 2015/16 and 2018/19 seasons

<sup>c</sup>Obesity, diabetes, immunopathy, nephropathy, neuropathy

<sup>d</sup>Two missing values for origin of admission in H1N1 seasons

<sup>e</sup>Including intermediate care and family-type facilities, etc.

<sup>f</sup>Including human metapneumovirus, human parainfluenza viruses, adenovirus, entero/rhinovirus (not differentiated) and human bocavirus

Abbreviations: ORV, other respiratory viruses; RSV, respiratory syncytial virus;

**Table 2.** Estimated influenza-associated hospitalization incidence (per 100,000), by age group and comorbidity status, Quebec hospital surveillance from 2012-13 to 2018-19

Age (months or years)	Health status <sup>a</sup>	Season and virus type /subtype predominance							
		Average all seasons	2012/13 (H3N2)	2013/14 (H1N1)	2014/15 (H3N2)	2015/16 (H1N1)	2016/17 (H3N2)	2017/18 (H3N2-B)	2018/19 (H1N1)
0-5m	Overall	416	750	50	489	385	358	370	544
	Comorbidity	NC	NC	NC	NC	NC	NC	NC	NC
	Healthy	NC	NC	NC	NC	NC	NC	NC	NC
	Ratio C/H	NC	NC	NC	NC	NC	NC	NC	NC
6-23m	Overall	255	172	230	183	437	160	189	470
	Comorbidity	1054	554	1028	754	1985	1290	552	1277
	Healthy	230	160	205	166	389	125	178	445
	Ratio C/H	4.6	3.5	5.0	4.5	5.1	10.3	3.1	2.9
2-4y	Overall	86	62	62	34	117	29	157	170
	Comorbidity	386	370	231	167	762	0	365	940
	Healthy	63	39	49	24	69	31	141	112
	Ratio C/H	6.1	9.5	4.7	7.0	11.0	0.0	2.6	8.4
5-17y	Overall	17	5	14	17	21	14	35	15
	Comorbidity	112	44	70	109	128	79	267	81
	Healthy	11	2	11	11	14	10	20	11
	Ratio C/H	10.2	22.0	6.4	9.9	9.1	7.9	13.4	7.4
18-64y	Overall	31	24	37	26	38	20	31	39
	Comorbidity	65	56	77	60	75	41	74	78
	Healthy	12	8	16	9	19	9	9	18
	Ratio C/H	5.4	7.0	4.8	6.7	3.9	4.6	8.2	4.3
65-74y	Overall	153	129	79	242	126	121	223	143
	Comorbidity	301	246	167	492	261	226	438	258
	Healthy	32	33	6	37	15	35	46	48
	Ratio C/H	9.4	7.5	27.8	13.3	17.4	6.5	9.5	5.4
75-84y	Overall	434	501	113	964	275	370	524	230
	Comorbidity	664	792	297	1457	421	561	820	337
	Healthy	118	109	0	300	78	113	125	87
	Ratio C/H	5.6	7.3	NC	4.9	5.4	5.0	6.6	3.9
75+y	Overall	561	663	123	1268	275	481	693	275
	Comorbidity	826	972	209	1928	402	725	1068	390
	Healthy	155	224	0	329	94	134	155	111
	Ratio C/H	5.3	4.3	NC	5.9	4.3	5.4	6.9	3.5
85+y	Overall	873	1113	148	2039	275	736	1067	377
	Comorbidity	1191	1434	238	3033	359	1072	1577	502
	Healthy	256	586	0	411	138	187	230	171
	Ratio C/H	4.7	2.4	NC	7.4	2.6	5.7	6.9	2.9
Overall	Overall	89	84	49	143	73	73	117	82
	Comorbidity	214	206	109	380	156	177	293	165
	Healthy	30	28	21	34	34	24	34	42
	Ratio C/H	7.1	7.4	5.2	11.2	4.6	7.4	8.6	3.9

<sup>a</sup> Chronic cardiac conditions, chronic respiratory conditions, obesity, diabetes, immunopathy, nephropathy and neuropathy.

Abbreviations: C, comorbidity; H, healthy; NC, not calculable

**Table 3.** Number needed to vaccinate to prevent one hospitalization by age group and comorbidity status, Quebec hospital surveillance from 2012-13 to 2018-19

Comorbidity status and age group	% of all hospitalizations	% unvaccinated <sup>a</sup> (partly preventable)	Incidence in unvaccinated (per 100,000)	NNV to prevent one hospitalization <sup>b</sup> assuming different vaccine effectiveness		
				VE=30%	VE=50%	VE=60%
All patients						
0-5 months	2.6%	NA	NA	NA	NA	NA
6-23 months	5.0%	79.2%	NE	NE	NE	NE
2-4 years	3.5%	94.2%	NE	NE	NE	NE
5-17 years	2.9%	84.9%	NE	NE	NE	NE
18-64 years	23.3%	72.5%	2.5	134,632	80,779	67,316
65-74 years	17.5%	56.9%	18.6	17,881	10,729	8,941
75-84 years	24.7%	43.7%	57.2	5,831	3,499	2,916
≥85 years	20.5%	40.2%	97.7	3,411	2,047	1,706
≥65 years	62.1%	46.2%	36.9	9,039	5,424	4,520
≥75 years	44.8%	42.1%	63.4	5,259	3,155	2,629
Patients with comorbidity						
0-5 months	NA	NA	NA	NA	NA	NA
6-23 months	0.7%	58.3%	NE	NE	NE	NE
2-4 years	1.2%	95.2%	NE	NE	NE	NE
5-17 years	1.1%	70.0%	NE	NE	NE	NE
18-64 years	16.4%	66.7%	4.9	68,375	41,025	34,187
65-74 years	15.1%	53.6%	34.5	9,655	5,793	4,828
75-84 years	21.6%	42.0%	54.8	3,932	2,359	1,966
≥85 years	17.8%	38.7%	134.3	2,482	1,489	1,241
≥65 years	54.5%	44.1%	62.4	5,339	3,203	2,670
≥75 years	39.4%	40.5%	100.2	3,325	1,995	1,663
Patients without comorbidity						
0-5 months	NA	NA	NA	NA	NA	NA
6-23 months	4.7%	82.1%	NE	NE	NE	NE
2-4 years	2.7%	93.8%	NE	NE	NE	NE
5-17 years	1.9%	93.9%	NE	NE	NE	NE
18-64 years	6.3%	87.5%	1.2	272,479	163,488	136,240
65-74 years	2.2%	79.5%	5.6	59,030	35,418	29,515
75-84 years	3.1%	55.6%	20.0	16,703	10,022	8,351
≥85 years	2.3%	51.2%	37.8	8,828	5,297	4,414
≥65 years	7.6%	61.2%	11.3	29,388	17,633	14,694
≥75 years	5.4%	53.7%	24.8	13,442	8,065	6,721

<sup>a</sup> Including those with unknown vaccination status (4% globally)


<sup>b</sup> Number needed to vaccinate to prevent one hospitalization using the following calculation:  $NNV =$

$$\frac{1}{Incidence\ unvaccinated - Incidence\ assuming\ VE\ of\ 50\%} \times 100,000$$

Abbreviation: NA, non-applicable; NE, non-estimable; NNV, number needed to vaccinate; VE, vaccine effectiveness

## FIGURES

**Figure 1.** Number of influenza hospitalizations in the Quebec hospital surveillance (2012-13 to 2018-19) by age group, comorbidity status and vaccination status, and vaccination coverage among adults by age group and comorbidity status (mean of both surveys)




Notes:


<sup>1</sup> Numbers over the columns are percentage of vaccinated among each age and risk subgroup (also represented by the upper grey area of each column)

<sup>2</sup> Vaccination coverages (VC) are the average of 2016 and 2018 Quebec's vaccination surveys. Estimations are representative for population with and without comorbidities for 3 age groups (18-64 years, 65-74 years and ≥75 years)


**Figure 2.** Estimated influenza-associated hospitalization incidence (per 100,000) by age group and by influenza A sub-type dominance season



**Figure 3.** Estimated influenza-associated hospitalization incidence (per 100,000) and confidence intervals, by age group and comorbidity status, Quebec hospital surveillance (2012-13 to 2018-19)



**Figure 4.** Estimated influenza-associated annual hospitalization rates (per 100,000) by vaccination status among adults with or without comorbidity, Quebec, 2012-13 to 2018-19



Note: Vertical lines in the bars represent the 95% confidence intervals